1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > DAINIPPON SUMITOMO PHARMA - Expectation From BBI-608 To Achieve FY2017 MTP Target Looks Unachievable!

Dainippon Sumitomo (DSP) is one of those Japanese pharma companies which has changed its orbit by successful US launch of Latuda (Lurasidone, dopamine-2, serotonin-2 and serotonin-7 receptors agonist schizophrenia/bipolar disorder) in the last two years. But DSP’s expectation to generate $650m by FY2017 from its lead compound BBI-608 from mCRC is way unachievable. Pipeline Cancer Stem Cell Inhibitors- from OncoMed/Celgene (OMP-21M18, OMP-52M51) And Bionomics (BNC-101) also need a close watch. On M & A front (Table 11), DSP’s R & D collaboration with Edison pharma for EP-743 to target mitochondrial disease, with Healios for iPS cell technology demonstrates its interest for developing first in class drug to target niche market, but they do not fill the gap which it needs to fulfill its FY2017 MTP targets.

Due to that, no possibility should be ruled out for DSP to do some M & A for late stage compound in oncology space or in CNS/Respiratory space. BBI-608 Optimism Is Too High – Lead Indication -mCRC Opportunity, Pipeline CSC Inhibitors- From OncoMed/Celgene (OMP-21M18, OMP-52M51) And Bionomics (BNC-101) Need A Close Watch- LATUDA: US Blockbuster potential is unavoidable from genericized schizophrenia/bipolar disorder market, while opportunities in bipolar maintenance, MDD with mixed features and IM Depo formulation will be limited due to …………APTIOM AND OTHER PIPELINE CANDIDATES….

Table Of Contents

DAINIPPON SUMITOMO PHARMA - Expectation From BBI-608 To Achieve FY2017 MTP Target Looks Unachievable!

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Bipolar disorder (BPD)  - Epidemiology Forecast To 2023

Bipolar disorder (BPD)  - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight “Bipolar disorder (BPD)  - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Bipolar disorder (BPD)  in seven major markets (US, France, Germany, Italy, ...

 Bipolar Disorder (Manic Depression)-Pipeline Insights, 2017

Bipolar Disorder (Manic Depression)-Pipeline Insights, 2017

  • $ 1250
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight’s, “ Bipolar Disorder (Manic Depression)-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Bipolar Disorde ...

Deep Brain Stimulators - Medical Devices Pipeline Assessment, 2016

Deep Brain Stimulators - Medical Devices Pipeline Assessment, 2016

  • $ 4000
  • Industry report
  • December 2016
  • by Global Data

Deep Brain Stimulators - Medical Devices Pipeline Assessment, 2016 Summary GlobalData's Medical Devices sector report, “Deep Brain Stimulators - Medical Devices Pipeline Assessment, 2016" provides an ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.